AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 201 min read$HIMS

Autor Deborah M. sold $467K of HIMS

Autor Deborah M. (Chief Policy Officer) sold 16,773 shares of Hims & Hers Health, Inc. (HIMS) at $27.85 ($0.47M total) on 2026-08-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Autor Deborah M.
Published Aug 20, 2026, 8:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 8:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$HIMS
Bearish
medium confidence
Mentioned
$HIMS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HIMSBearishLow
01

Why it matters

The disclosed sale provides fresh data for traders monitoring insider activity.

02

Market read

New insider sale information, modest in size, may influence short-term price action.

03

What to watch

The insider retained a sizable position, indicating continued confidence.

Relevance 3/10Novelty 4/10Timing: post-market

Background

Form 4 filings disclose insider transactions; a 10b5-1 plan sale by a senior officer is publicly reported.

Company-level read

Ticker impact

$HIMSBearishMedium confidence
Context

Chief Policy Officer sold 16,773 shares for $467K via a 10b5-1 plan, reducing her stake to 48,961 shares.

Expected impact

Possible modest downward pressure in the near term.

Evidence & confidence

Sale size is modest relative to market cap, but insider sales often trigger short-term sell sentiment.

Market effects

Sector

Minimal impact on the telehealth sector.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event, not a negative signal.

Key entities

  • Company
    Hims & Hers Health, Inc.

    Provider of telehealth and wellness services, ticker HIMS.

  • Person
    Deborah M. Autor

    Chief Policy Officer of Hims & Hers Health.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

HIMS insider trading history →

Related articles

SEP 22
$HIMSMed

Hims & Hers Suit Spotlights Health Data-Sharing Privacy Risks

The FTC, along with California and Utah regulators, filed a lawsuit against Hims & Hers on July 29, alleging privacy risks related to health data-sharing. The complaint was filed in the U.S. District Court for the Northern District of California. This legal action highlights concerns over consumer data protection in the health sector.

law360.com1 min
SEP 19
$HIMSMed

Telehealth companies keep exposing their customers' medical data. What should they do?

The FTC sued Hims & Hers for allegedly disclosing customer health data, signing users up for hard-to-cancel subscriptions, and bypassing real-time doctor consultations. Hims disputes the claims. Experts note federal laws often don't apply to telehealth companies, leading to data sharing with advertisers. Recent studies found many telehealth services lack proper physician consultations, especially for GLP-1 drugs. State laws offer some protections, but enforcement is limited. Privacy experts reco

newsday.com2 min
SEP 18
$HIMSHighAI 8/10

Class-action lawsuit filed against Hims & Hers following FTC complaint

A class-action lawsuit was filed against Hims & Hers (HIMS) on behalf of investors who acquired securities between 4 August 2025 and 29 July 2026, following an FTC complaint. The FTC alleges deceptive billing and unlawful sharing of health information. HIMS shares fell 14.73% on the news, closing at $25.00. The company denies the allegations.

dig.watch2 min
SEP 17
$HIMSHighAI 8/10

HIMS Stock Snaps 2-Day Climb: Analyst Says Record Subscriber Growth ‘Not Enough’ To Offset Margin Slide

Hims & Hers Health (HIMS) stock fell 4% on Tuesday despite record subscriber growth and a Q2 revenue beat. Revenue rose 38% to $753M, but adjusted EBITDA dropped 27% to $60.3M. Morningstar noted margin concerns, while Deutsche Bank raised its price target to $26. The company raised its 2026 revenue forecast but lowered its EBITDA guidance.

stocktwits.com2 min
SEP 14
$HIMSMed

Why Hims & Hers Stock Is Suddenly Soaring

Hims & Hers Health (HIMS) stock surged following a $32 price target from JPMorgan, which projects $1.1B in GLP-1 weight-loss revenues by 2026. The rally was also driven by a new 3x leveraged long product on the LSE. The company has 3M subscribers and growing revenue, but faces debt and margin pressures.

tipranks.com2 min
SEP 11
$HIMSMed

JPMorgan cautious on Hims & Hers on GLP-1 transition risk

JPMorgan initiated coverage of Hims & Hers Health with a Neutral rating and a $32 price target for 2027. The firm acknowledges the company's growth but highlights risks in its transition to branded weight-loss drugs. Hims has 2.9 million subscribers and a partnership with Novo Nordisk for Wegovy shipments. JPMorgan projects 2026 GLP-1 revenue of $1.1 billion and long-term revenue growth to over $6.5 billion by 2030, but cautions on execution risks.

investing.com2 min